Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Basil S Lewis

Showing results (151-160 of 240) with videos related to

Pageof 24
Sort By:
The Lancet. Neurology|May 11, 2012
Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trialJ Donald Easton, Renato D Lopes, M Cecilia Bahit, et al.
International Journal of Cardiology|November 7, 2013
Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trialMaria Cecilia Bahit, Renato D Lopes, Daniel M Wojdyla, et al.
JACC. Heart Failure|June 27, 2024
Vericiguat and Cardiovascular Outcomes in Heart Failure by Baseline Diabetes Status: Insights From the VICTORIA TrialMuhammad Shahzeb Khan, Javed Butler, Rebecca Young, et al.
Circulation|July 22, 2016
Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial InfarctionErin A Bohula, Marc P Bonaca, Eugene Braunwald, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|February 1, 2018
Antithrombotic therapy use and clinical outcomes following thrombo-embolic events in patients with atrial fibrillation: insights from ARISTOTLEShinya Goto, Peter Merrill, Lars Wallentin, et al.
International Journal of Cardiology|July 17, 2012
Age, treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: insights from the EARLY ACS trialRenato D Lopes, Jennifer A White, Pierluigi Tricoci, et al.
American Heart Journal|December 5, 2016
On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT)Michael A Blazing, Robert P Giugliano, James A de Lemos, et al.
European Heart Journal|November 11, 2017
Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular PharmacotherapyAlexander Niessner, Juan Tamargo, Lorenz Koller, et al.
European Heart Journal|January 13, 2017
Comprehensive efforts to increase adherence to statin therapyAlexander Vonbank, Stefan Agewall, Keld Per Kjeldsen, et al.
Circulation|September 1, 2010
Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trialStefan James, Andrzej Budaj, Philip Aylward, et al.
Pageof 24

Showing results (151-160 of 240) with videos related to

Sort By:
Pageof 24
The Lancet. Neurology|May 11, 2012
Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trialJ Donald Easton, Renato D Lopes, M Cecilia Bahit, et al.
International Journal of Cardiology|November 7, 2013
Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trialMaria Cecilia Bahit, Renato D Lopes, Daniel M Wojdyla, et al.
JACC. Heart Failure|June 27, 2024
Vericiguat and Cardiovascular Outcomes in Heart Failure by Baseline Diabetes Status: Insights From the VICTORIA TrialMuhammad Shahzeb Khan, Javed Butler, Rebecca Young, et al.
Circulation|July 22, 2016
Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial InfarctionErin A Bohula, Marc P Bonaca, Eugene Braunwald, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|February 1, 2018
Antithrombotic therapy use and clinical outcomes following thrombo-embolic events in patients with atrial fibrillation: insights from ARISTOTLEShinya Goto, Peter Merrill, Lars Wallentin, et al.
International Journal of Cardiology|July 17, 2012
Age, treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: insights from the EARLY ACS trialRenato D Lopes, Jennifer A White, Pierluigi Tricoci, et al.
American Heart Journal|December 5, 2016
On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT)Michael A Blazing, Robert P Giugliano, James A de Lemos, et al.
European Heart Journal|November 11, 2017
Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular PharmacotherapyAlexander Niessner, Juan Tamargo, Lorenz Koller, et al.
European Heart Journal|January 13, 2017
Comprehensive efforts to increase adherence to statin therapyAlexander Vonbank, Stefan Agewall, Keld Per Kjeldsen, et al.
Circulation|September 1, 2010
Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trialStefan James, Andrzej Budaj, Philip Aylward, et al.
Pageof 24